• Explore /
  • Poster
  • / Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients.

Window of opportunity trial to characterize the safety, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in cisplatin-ineligible muscle invasive bladder cancer patients.

Abstract Poster

Authors

null

John Arthur Taylor III

Department of Urology, University of Kansas Medical Center, Kansas City, KS

John Arthur Taylor III, Robyn Wood , Tammy Ham , Crista Casey , Prasad Dandawate , Greg Reed , Benjamin L. Woolbright , Michael Jay Baltezor , Roy A. Jensen , Michael Dalton , Valentina Zhukova-Harrill , William McCulloch , Shrikant Anant , Scott James Weir

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03348514

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS604)

Abstract #

TPS604

Poster Bd #

N22

Abstract Disclosures

Similar Posters

First Author: Manish R. Patel

First Author: Scott James Weir

First Author: Andrea Necchi

First Author: Tara L. Lin